AGC Inc. Q4 FY2025 earnings call

• Financial Performance Review: FY '25 net sales flat, operating profit slightly up; FY '26 outlook: operating profit expected to increase driven by Life Science recovery, ROE to improve to 5.2%.
• Segment-Specific Initiatives: Architectural Glass to focus on pricing and productivity in Asia, maintain price and reduce costs in Europe and Americas; Automotive to improve product mix, pricing, and structural reform; Electronics to continue profit improvement measures; Chemicals to increase fluorine-related product shipments and expand in Southeast Asia; Life Science to reduce losses and increase sales through facility expansions and order growth.
• Profitability Improvement Strategies: Lower costs, adjust pricing policies, increase product value, manage inventory, consider business exits; R&D focus on innovation, new products, and new markets.

Architectural Glass:

• Net sales increased by JPY 3.2 billion to JPY 441.1 billion, operating profit rose by JPY 0.9 billion to JPY 17.3 billion.
• Asia: Net sales decreased due to lower shipments and prices; Europe and Americas: Net sales increased by JPY 7.6 billion benefiting from pricing policy and weaker yen.
• Subsegment ratio of OP: approximately 20% for Asia and 80% for Europe and Americas.

Automotive:

• Net sales increased by JPY 21.8 billion to JPY 520.6 billion, operating profit increased by JPY 15.3 billion to JPY 29.3 billion.
• Shipments declined in Europe but increased in Japan; improvement in product mix, pricing policies, and weak yen contributed.

Electronics:

• Net sales decreased by JPY 9.5 billion to JPY 355.1 billion, operating profit decreased by JPY 6.9 billion to JPY 47.5 billion.
• Display: Net sales increased by JPY 5.5 billion due to higher shipments in LCD glass substrates; Electronic Materials: Revenue decreased by JPY 15.1 billion due to transition period and EUV mask blanks shipment decline.

Chemicals:

• Net sales were JPY 584.2 billion, down JPY 9.4 billion; operating profit was JPY 53 billion, down JPY 3.7 billion.
• Essential Chemicals: Net sales down due to lower PVC sales price; Performance Chemicals: Net sales increased by JPY 18.2 billion due to pricing policies and higher shipments of fluorine-related products.

Life Science:

• Net sales were JPY 133.1 billion, down JPY 8.1 billion; operating loss was JPY 22.3 billion, down JPY 1.1 billion.
• Sales of small molecule pharmaceuticals and agrochemical CDMO remained steady; biopharmaceutical CDMO net sales affected by disappearance of one-off revenues and closure of U.S. Colorado sites.

Strategic Businesses:

• Net sales were JPY 501.5 billion, down JPY 1.8 billion year-on-year; operating profit was JPY 58.7 billion, down JPY 8.6 billion.

• FY '26 forecast: Net sales JPY 2.2 trillion (increase of JPY 141.2 billion Y-o-Y), operating profit JPY 150 billion (increase of JPY 22.5 billion), ROE to 5.2%.
• Segment outlooks: Architectural Glass expects Asia shipments to increase, Europe and Americas to focus on price and cost; Automotive expects shipment decline but product mix and pricing to help; Electronics expects LCD glass substrate shipments to decline slightly, semiconductor-related materials shipments to increase; Chemicals expects fluorine-related product and chlor-alkali shipments to increase; Life Science expects synthetic pharmaceuticals and agrochemical CDMO sales to increase, biopharmaceutical CDMO losses to reduce.
• Strategic businesses: Net sales projected to JPY 560 billion, operating profit to JPY 80 billion, driven by Life Science profit improvement.

• Market and Operational Risks: Uncertain geopolitical situation, challenging market conditions in some regions (e.g., Southeast Asia for Architectural Glass, China for Essential Chemicals), transition period in Electronics materials leading to revenue decline, uncertainties in Life Science business recovery.
• Supply Chain Risks: Impact of precious metal price fluctuations on procurement, potential delays in certification for EUV mask blanks development.

Q: Regarding ROE, ROCE, and challenges in Life Science and Essential Chemicals, what is the time frame and options for review?

A: For Life Science, recovery may take until 2027 due to order expansion lag; for Essential Chemicals, improvement will take time leveraging customer relationships. FY '26 pretax profit expected to be affected by normal factors but no major unexpected expenses.

Q: How does the 2026 full year forecast compare to 2025?

A: 2026 net sales increase due to positive contributions from Architectural Glass, Chemicals, and Life Science; profit increase from Architectural Glass pricing, Life Science sales growth, and Chemicals shipment increases.

Q: What are the future investment policies?

A: Future investments will focus on maintenance and updating rather than major expansions, with roughly half of investments for maintenance.

Q: Is the operating profit of JPY 150 billion a commitment?

A: Intended as a commitment, based on market requirements and achievable level despite past failures.

Q: Explain the drivers behind the expected profit reduction in Electronics.

A: Slight decline in display shipments, impact of weaker yen, transitional period in optoelectronics materials moving to higher value-added products.

Q: Update on Life Science Bio Colorado site divestiture progress.

A: Still in negotiation with multiple candidates, aiming to conclude within the first quarter.

Q: Outlook for EUV mask blanks shipment from '25 to '26.

A: Expect higher profit year-on-year but moderate recovery, dependent on customer recovery and base expansion.

Q: Capital allocation and shareholder return policy.

A: Cash allocation not finalized, share buyback to be decided comprehensively; return policy to be revisited from '27 onwards.